Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
PETS's Cash-to-Debt is ranked higher than
99% of the 364 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.53 vs. PETS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
PETS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.79
PETS's Equity-to-Asset is ranked higher than
96% of the 359 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. PETS: 0.79 )
Ranked among companies with meaningful Equity-to-Asset only.
PETS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.13  Med: 0.87 Max: 0.95
Current: 0.79
-0.13
0.95
Interest Coverage No Debt
PETS's Interest Coverage is ranked higher than
99% of the 328 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.81 vs. PETS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PETS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 7
Altman Z-Score: 21.34
Beneish M-Score: -3.75
WACC vs ROIC
5.26%
70.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 16.19
PETS's Operating Margin % is ranked higher than
94% of the 364 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.88 vs. PETS: 16.19 )
Ranked among companies with meaningful Operating Margin % only.
PETS' s Operating Margin % Range Over the Past 10 Years
Min: 10.92  Med: 14.03 Max: 17.02
Current: 16.19
10.92
17.02
Net Margin % 10.34
PETS's Net Margin % is ranked higher than
94% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.94 vs. PETS: 10.34 )
Ranked among companies with meaningful Net Margin % only.
PETS' s Net Margin % Range Over the Past 10 Years
Min: 6.99  Med: 8.89 Max: 10.91
Current: 10.34
6.99
10.91
ROE % 29.05
PETS's ROE % is ranked higher than
92% of the 357 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.73 vs. PETS: 29.05 )
Ranked among companies with meaningful ROE % only.
PETS' s ROE % Range Over the Past 10 Years
Min: 18.7  Med: 26.36 Max: 33.12
Current: 29.05
18.7
33.12
ROA % 24.89
PETS's ROA % is ranked higher than
98% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.40 vs. PETS: 24.89 )
Ranked among companies with meaningful ROA % only.
PETS' s ROA % Range Over the Past 10 Years
Min: 16.88  Med: 23.59 Max: 29.73
Current: 24.89
16.88
29.73
ROC (Joel Greenblatt) % 114.37
PETS's ROC (Joel Greenblatt) % is ranked higher than
96% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.30 vs. PETS: 114.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PETS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 91.28  Med: 106.27 Max: 194.27
Current: 114.37
91.28
194.27
3-Year Revenue Growth Rate 1.60
PETS's 3-Year Revenue Growth Rate is ranked lower than
64% of the 331 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. PETS: 1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PETS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.3  Med: 9.7 Max: 58
Current: 1.6
-0.3
58
3-Year EBITDA Growth Rate 9.50
PETS's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 299 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.70 vs. PETS: 9.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PETS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -8.7  Med: 9.5 Max: 106.3
Current: 9.5
-8.7
106.3
3-Year EPS without NRI Growth Rate 9.10
PETS's 3-Year EPS without NRI Growth Rate is ranked higher than
53% of the 265 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.60 vs. PETS: 9.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PETS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9  Med: 9.1 Max: 104.1
Current: 9.1
-9
104.1
GuruFocus has detected 2 Warning Signs with PetMed Express Inc $PETS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PETS's 30-Y Financials

Financials (Next Earnings Date: 2017-10-24 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

PETS Guru Trades in Q3 2016

Chuck Royce 401,500 sh (unchged)
Paul Tudor Jones Sold Out
John Buckingham 100,190 sh (-1.79%)
Jim Simons 1,567,915 sh (-5.68%)
Ken Fisher 115,453 sh (-22.02%)
» More
Q4 2016

PETS Guru Trades in Q4 2016

Jim Simons 1,597,700 sh (+1.90%)
John Buckingham 96,699 sh (-3.48%)
Chuck Royce 309,600 sh (-22.89%)
Ken Fisher 60,164 sh (-47.89%)
» More
Q1 2017

PETS Guru Trades in Q1 2017

Ken Fisher 86,359 sh (+43.54%)
Jim Simons 1,786,315 sh (+11.81%)
John Buckingham 97,720 sh (+1.06%)
Chuck Royce 309,600 sh (unchged)
» More
Q2 2017

PETS Guru Trades in Q2 2017

Lee Ainslie 11,598 sh (New)
Joel Greenblatt 32,374 sh (New)
Ken Fisher 121,321 sh (+40.48%)
Chuck Royce 309,600 sh (unchged)
John Buckingham Sold Out
Jim Simons 1,647,400 sh (-7.78%)
» More
» Details

Insider Trades

Latest Guru Trades with PETS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Add 40.48%$20.14 - $41.06 $ 35.3315%121,321
Joel Greenblatt 2017-06-30 New Buy0.02%$20.14 - $41.06 $ 35.3315%32,374
Ken Fisher 2017-03-31 Add 43.54%$19.26 - $23.66 $ 35.3367%86,359
Ken Fisher 2016-12-31 Reduce -47.89%$19.28 - $23.49 $ 35.3365%60,164
Ken Fisher 2016-09-30 Reduce -22.02%$18.76 - $20.94 $ 35.3375%115,453
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 541940    SIC: 5912
Compare:NYSE:GNC, OTCPK:HEWA, OTCPK:OMHE, OTCPK:MYDP, NYSE:RAD, NAS:WBA » details
Traded in other countries:PQM.Germany,
Headquarter Location:USA
PetMed Express Inc is a nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications and other health products for dogs, cats, and horses direct to the consumer.

PetMed Express Inc was incorporated in the state of Florida in January 1996. The Company is a nationwide pet pharmacy. It markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. It markets its products through national television, online, and direct mail/print advertising campaigns, which aim to increase the recognition of the "1-800-PetMeds" brand name and "PetMeds". It offers a selection of products for dogs and cats. Its current product line contains approximately 3,000 SKUs of the popular pet medications, health products, and supplies. These products include a majority of the brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Revolution, and Rimadyl. The Company offers its products through three main sales channels: Internet through its website, telephone contact center through its toll-free number, and direct mail/print through 1-800-PetMeds catalogs, brochures, and postcards. It have designed its website and catalogs to provide a convenient, cost-effective, and informative shopping experience that encourages consumers to purchase products important for a pet's health and quality of life. Its customers are located throughout the United States, with approximately 50% of customers residing in California, Florida, New York, Texas, Pennsylvania, Virginia, North Carolina, and New Jersey. Its primary focus has been on retail customers. Its competitors consist of veterinarians, and online and traditional retailers. Its trademarks include PetMed Express and Design, 1888PetMeds and Design, 1-800-PetMeds and Design, 1-800-PetMeds, and PetMeds. The Company is subject to regulation by the State of Florida and is licensed as a community pharmacy by the Florida Board of Pharmacy.

Top Ranked Articles about PetMed Express Inc

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against PetMed Express, Inc. – PETS
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PetMed Express, Inc. of Class Action Lawsuit and Upcoming Deadline - PETS
PETMED SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against PetMed Express, Inc. - (PETS)
Safirstein Metcalf LLP Announces that A Class Action Has Been Filed Against PetMed Express, Inc. – PETS
PETMED SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against PetMed Express, Inc. - (PETS)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against PetMed Express, Inc. and Certain Officers – PETS
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In PetMed Express, Inc. (Nasdaq:PETS) To Contact Brower Piven Before The Lead Plaintiff Deadline
Lifshitz & Miller LLP Announces Investigation of Ellie Mae, Inc., First Bitcoin Capital Corp., GlobalSCAPE, Inc., PetMed Express, Inc., Stryker Corporation, TransDigm Group Incorporated and Zillow Group, Inc.
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against PetMed Express, Inc. (PETS)
PETMED SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against PetMed Express, Inc. - (PETS)

Ratios

vs
industry
vs
history
PE Ratio 27.17
PETS's PE Ratio is ranked lower than
77% of the 304 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.17 vs. PETS: 27.17 )
Ranked among companies with meaningful PE Ratio only.
PETS' s PE Ratio Range Over the Past 10 Years
Min: 11.34  Med: 16.6 Max: 37.21
Current: 27.17
11.34
37.21
Forward PE Ratio 30.67
PETS's Forward PE Ratio is ranked lower than
94% of the 65 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.76 vs. PETS: 30.67 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 27.17
PETS's PE Ratio without NRI is ranked lower than
77% of the 302 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.55 vs. PETS: 27.17 )
Ranked among companies with meaningful PE Ratio without NRI only.
PETS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.34  Med: 16.6 Max: 37.21
Current: 27.17
11.34
37.21
Price-to-Owner-Earnings 18.13
PETS's Price-to-Owner-Earnings is ranked higher than
50% of the 203 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.21 vs. PETS: 18.13 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PETS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.6  Med: 18.38 Max: 49.49
Current: 18.13
8.6
49.49
PB Ratio 7.32
PETS's PB Ratio is ranked lower than
96% of the 352 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.77 vs. PETS: 7.32 )
Ranked among companies with meaningful PB Ratio only.
PETS' s PB Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4.32 Max: 10.03
Current: 7.32
2.33
10.03
PS Ratio 2.79
PETS's PS Ratio is ranked lower than
94% of the 356 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. PETS: 2.79 )
Ranked among companies with meaningful PS Ratio only.
PETS' s PS Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.54 Max: 3.85
Current: 2.79
0.84
3.85
Price-to-Free-Cash-Flow 18.02
PETS's Price-to-Free-Cash-Flow is ranked lower than
55% of the 143 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.04 vs. PETS: 18.02 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PETS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.83  Med: 17.76 Max: 2097.27
Current: 18.02
7.83
2097.27
Price-to-Operating-Cash-Flow 15.05
PETS's Price-to-Operating-Cash-Flow is ranked lower than
81% of the 187 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.78 vs. PETS: 15.05 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PETS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.65  Med: 15.59 Max: 36.37
Current: 15.05
7.65
36.37
EV-to-EBIT 15.91
PETS's EV-to-EBIT is ranked lower than
68% of the 316 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.11 vs. PETS: 15.91 )
Ranked among companies with meaningful EV-to-EBIT only.
PETS' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.7  Med: 9.2 Max: 22.2
Current: 15.91
4.7
22.2
EV-to-EBITDA 15.30
PETS's EV-to-EBITDA is ranked lower than
79% of the 324 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.79 vs. PETS: 15.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
PETS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.5  Med: 8.9 Max: 21.3
Current: 15.3
4.5
21.3
EV-to-Revenue 2.55
PETS's EV-to-Revenue is ranked lower than
94% of the 361 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.58 vs. PETS: 2.55 )
Ranked among companies with meaningful EV-to-Revenue only.
PETS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 1.3 Max: 3.6
Current: 2.55
0.5
3.6
PEG Ratio 4.09
PETS's PEG Ratio is ranked lower than
74% of the 179 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.12 vs. PETS: 4.09 )
Ranked among companies with meaningful PEG Ratio only.
PETS' s PEG Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.72 Max: 72.64
Current: 4.09
0.33
72.64
Shiller PE Ratio 33.99
PETS's Shiller PE Ratio is ranked lower than
85% of the 86 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 22.04 vs. PETS: 33.99 )
Ranked among companies with meaningful Shiller PE Ratio only.
PETS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.11  Med: 18.32 Max: 50.21
Current: 33.99
13.11
50.21
Current Ratio 3.71
PETS's Current Ratio is ranked higher than
96% of the 360 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.22 vs. PETS: 3.71 )
Ranked among companies with meaningful Current Ratio only.
PETS' s Current Ratio Range Over the Past 10 Years
Min: 0.29  Med: 7.03 Max: 17.46
Current: 3.71
0.29
17.46
Quick Ratio 2.81
PETS's Quick Ratio is ranked higher than
95% of the 360 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.76 vs. PETS: 2.81 )
Ranked among companies with meaningful Quick Ratio only.
PETS' s Quick Ratio Range Over the Past 10 Years
Min: 0.11  Med: 4.42 Max: 14.61
Current: 2.81
0.11
14.61
Days Inventory 42.45
PETS's Days Inventory is ranked lower than
57% of the 355 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.51 vs. PETS: 42.45 )
Ranked among companies with meaningful Days Inventory only.
PETS' s Days Inventory Range Over the Past 10 Years
Min: 42.45  Med: 63.9 Max: 78.88
Current: 42.45
42.45
78.88
Days Sales Outstanding 2.93
PETS's Days Sales Outstanding is ranked higher than
85% of the 274 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.78 vs. PETS: 2.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
PETS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.31  Med: 2.9 Max: 4.79
Current: 2.93
2.31
4.79
Days Payable 34.38
PETS's Days Payable is ranked lower than
65% of the 269 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 43.02 vs. PETS: 34.38 )
Ranked among companies with meaningful Days Payable only.
PETS' s Days Payable Range Over the Past 10 Years
Min: 11.53  Med: 13.73 Max: 34.38
Current: 34.38
11.53
34.38

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.19
PETS's Dividend Yield % is ranked lower than
52% of the 477 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.95 vs. PETS: 2.19 )
Ranked among companies with meaningful Dividend Yield % only.
PETS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.51  Med: 4.08 Max: 5.85
Current: 2.19
0.51
5.85
Dividend Payout Ratio 0.59
PETS's Dividend Payout Ratio is ranked higher than
52% of the 289 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.33 vs. PETS: 0.59 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PETS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.68 Max: 0.78
Current: 0.59
0.26
0.78
3-Year Dividend Growth Rate 4.80
PETS's 3-Year Dividend Growth Rate is ranked lower than
63% of the 184 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.40 vs. PETS: 4.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PETS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 26
Current: 4.8
0
26
Forward Dividend Yield % 2.23
PETS's Forward Dividend Yield % is ranked lower than
54% of the 464 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.20 vs. PETS: 2.23 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.10
PETS's 5-Year Yield-on-Cost % is ranked lower than
56% of the 526 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.96 vs. PETS: 3.10 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PETS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.72  Med: 5.78 Max: 8.28
Current: 3.1
0.72
8.28
3-Year Average Share Buyback Ratio -0.60
PETS's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 207 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.70 vs. PETS: -0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PETS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -0.4 Max: 4.5
Current: -0.6
-45.6
4.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 17.32
PETS's Price-to-Net-Cash is ranked lower than
65% of the 31 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.79 vs. PETS: 17.32 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PETS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.77  Med: 8.79 Max: 34.59
Current: 17.32
3.77
34.59
Price-to-Net-Current-Asset-Value 10.58
PETS's Price-to-Net-Current-Asset-Value is ranked lower than
76% of the 129 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.30 vs. PETS: 10.58 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PETS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.56  Med: 5.89 Max: 40
Current: 10.58
2.56
40
Price-to-Tangible-Book 7.39
PETS's Price-to-Tangible-Book is ranked lower than
89% of the 314 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.07 vs. PETS: 7.39 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PETS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.37  Med: 4.96 Max: 243.33
Current: 7.39
2.37
243.33
Price-to-Intrinsic-Value-Projected-FCF 2.59
PETS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
79% of the 228 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.47 vs. PETS: 2.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PETS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.54  Med: 1.3 Max: 6.04
Current: 2.59
0.54
6.04
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.54
PETS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
99.99% of the 54 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.36 vs. PETS: 2.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
PETS' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.45  Med: 0.55 Max: 2.91
Current: 2.54
0.45
2.91
Price-to-Median-PS-Value 1.83
PETS's Price-to-Median-PS-Value is ranked lower than
93% of the 334 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. PETS: 1.83 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PETS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1 Max: 2.1
Current: 1.83
0.28
2.1
Price-to-Peter-Lynch-Fair-Value 3.59
PETS's Price-to-Peter-Lynch-Fair-Value is ranked lower than
93% of the 102 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.71 vs. PETS: 3.59 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
PETS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.55  Med: 0.79 Max: 4.12
Current: 3.59
0.55
4.12
Price-to-Graham-Number 2.99
PETS's Price-to-Graham-Number is ranked lower than
88% of the 265 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.48 vs. PETS: 2.99 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PETS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.09  Med: 1.96 Max: 5.88
Current: 2.99
1.09
5.88
Earnings Yield (Greenblatt) % 6.34
PETS's Earnings Yield (Greenblatt) % is ranked lower than
58% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.52 vs. PETS: 6.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PETS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.5  Med: 10.9 Max: 21.2
Current: 6.34
4.5
21.2
Forward Rate of Return (Yacktman) % 10.44
PETS's Forward Rate of Return (Yacktman) % is ranked higher than
55% of the 244 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.90 vs. PETS: 10.44 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PETS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.2  Med: 15.2 Max: 65.7
Current: 10.44
1.2
65.7

More Statistics

Revenue (TTM) (Mil) $256.35
EPS (TTM) $ 1.30
Beta0.51
Short Percentage of Float37.85%
52-Week Range $18.90 - 50.90
Shares Outstanding (Mil)20.60

Analyst Estimate

Mar18 Mar19
Revenue (Mil $)
EPS ($) 1.17 1.40
EPS without NRI ($) 1.17 1.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PETS

Headlines

Articles On GuruFocus.com
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against PetMed Expr Sep 20 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PetMe Sep 16 2017 
PETMED SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVEST Sep 15 2017 
Safirstein Metcalf LLP Announces that A Class Action Has Been Filed Against PetMed Express, Inc. â Sep 11 2017 
PETMED SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Pl Sep 08 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against PetMed Express Sep 07 2017 
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Sep 06 2017 
Lifshitz & Miller LLP Announces Investigation of Ellie Mae, Inc., First Bitcoin Capital Corp., Globa Aug 30 2017 
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against PetMed Express, Aug 29 2017 
PETMED SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVEST Aug 29 2017 

More From Other Websites
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against PetMed... Sep 20 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PetMed... Sep 19 2017
3 Strong Buy Stocks to Grab on the Dip Sep 19 2017
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Sep 19 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action... Sep 18 2017
PETMED SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS... Sep 15 2017
At $36.71, Is PetMed Express Inc (PETS) A Buy? Sep 15 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action... Sep 15 2017
Cramer's lightning round: Here's where Qualcomm went wron... Sep 13 2017
Safirstein Metcalf LLP Announces that A Class Action Has Been Filed Against PetMed Express, Inc. –... Sep 11 2017
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against... Sep 11 2017
PETMED SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead... Sep 08 2017
PetMed Express, Inc. : PETS-US: Dividend Analysis : August 07th, 2017 (record date) : By the numbers... Sep 08 2017
PETS LOSS NOTICE: Rosen Law Firm Reminds PetMed Express, Inc. Investors of Important Deadline in... Sep 08 2017
Deadline Alert: GPM Reminds Investors of Upcoming Deadline in the Class Action Lawsuit Against... Sep 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}